Today, I list 4 biopharmas I feel offer strong upside potential in the short and midterm. With these catalysts quickly approaching, we can expect some nice shorter term appreciation under normal market conditions. I feel the 4 stocks I list…
Tag: $GSK
Pozen: An Undervalued Investment And Catalyst Trade Opportunity
Small cap biopharmas that make for good long term investments are hard to find. Most small cap biopharmas burn a ton of cash while developming treatments for a variety of ailments and rare diseases. Today, we focus on Pozen (NASDAQ:POZN)…
Synta Pharma: Poised For A Breakout With 4 Near Term Catalysts
Synta Pharmaceuticals Corp. (NASDAQ: SNTA)is a biopharmaceutical company focusing on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. The company has two drug…
11/30/12 Catalyst Trade And Speculation Investment List
Alexza Pharma (NASDAQ: ALXA) Alexza engages in the research, development, and commercialization of novel proprietary products for the acute treatment of central nervous system conditions worldwide. Its product candidates are based on a proprietary technology, the Staccato system, which vaporizes…
Upcoming BioPharma Catalyst Trades to Consider
Trading BioPhama stocks before a catalyst event, if done correctly can be a very profitable proposition, but if traded in a wrong manner, can cause losses. I remarked in an article from March of this year that Horizon Pharma (NASDAQ:…
5 Biotech Stocks Poised For Nice Upside Gains
The following 5 biotech companies have strong catalysts and/or strong chart signals that indicate a trade to the long side could be in order. With the current choppy markets, opportunities for long trades are few and far between. I will…
Amicus Therapeutics Should See a Big Upside Move On Positive Phase 3 Data
One company that has really received a ton of attention lately has been Sarepta Therapeutics (SRPT). Only a few weeks ago, the stock was trading in the $3 to $4 range. On 10/3/12, the company announced that it received positive…
